Apollomics

APLMNasdaq United States Health Care Biotechnology: Pharmaceutical Preparations

Market cap

$67.768 M

$23.40 -1.35%

Close of 23 Sept 2026

Revenue

—

Not reported

Earnings

—

Not reported

Shares outstanding

2,196,052

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Other share classes

Apollomics lists more than one class of stock. Company figures above cover all classes combined.

APLMW

Biotechnology: Pharmaceutical Preparations, ranked by market cap

All 500 →

#330Tenax TherapeuticsTENX$71.1M
#331Pliant TherapeuticsPLRX$69.7M
#332ApollomicsAPLM$67.8M
#333Connect BiopharmaCNTB$67.4M
#334Gossamer BioGOSS$67.2M

Insiders buying

All insider buying →

3 open-market purchases by officers and directors of Apollomics, worth $8.25M. Grants and option exercises are excluded.

Hung-Wen ChenChief Executive Officer$7.55M
536,667 shares at $14.07 on 14 Aug 2026 · filed 17 Aug 2026
Peter Kuan-How LinChief Financial Officer$400.0K
26,667 shares at $15.00 on 14 Aug 2026 · filed 17 Aug 2026
Yi-Kuei ChenChief Operating Officer$300.0K
20,000 shares at $15.00 on 14 Aug 2026 · filed 17 Aug 2026

What if Apollomics were worth as much as…

Open the what-if tool →

Gold $29.8T

$10,306,071

Per share 440,430× higher

Bitcoin $1.69T

$584,975.62

Per share 24,999× higher

Nvidia $5.43T

$1,876,620

Per share 80,197× higher

Or at a round number

$100.0M $200.0M $500.0M $1.00B

Where these numbers come from

Share counts and financials for Apollomics are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 24 Sept 2026. Read the methodology.